Fibrinogen-Coated Albumin Nanospheres Mobilize Endogenous Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies for renal failure are ineffective, costly, and carry risks such as tumor formation from external stem cells, necessitating a more efficient and safer method to mobilize patient-derived stem cells for renal repair.
Innovation Solution
Administration of a therapeutically effective amount of albumin nanoparticle suspension containing fibrinogen-coated albumin spheres (FAS) to increase stem cell concentrations and enhance their functionality in vivo, mobilizing them towards renal trauma sites to treat renal failure and damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If external stem cells are administered to treat renal failure, then renal repair may be achieved, but the risk of tumor formation increases and costs increase
Solution Approach 1:
The invention mobilizes the patient's own endogenous stem cells from bone marrow to the kidney injury site rather than administering external stem cells. This self-service approach eliminates the risk of tumor formation from external cells while reducing treatment costs. The FAS nanoparticles act as a mobilization agent that triggers the patient's own regenerative capacity.
Solution Approach 2:
Fibrinogen-coated albumin spheres (FAS) serve as an intermediary substance that mediates between the bone marrow and kidney injury site. The FAS nanoparticles bind to endothelial cells and activate stem cell mobilization pathways, indirectly facilitating renal repair without direct cell transplantation.
2Reliability
If external stem cells are administered to treat renal failure, then renal repair may be achieved, but treatment costs increase
Solution Approach 1:
By utilizing the patient's own endogenous stem cells rather than purchasing external stem cell products, the treatment significantly reduces costs. The FAS mobilization strategy leverages the body's existing regenerative resources, eliminating the need for expensive cell procurement, processing, and transplantation procedures.
Solution Approach 2:
The FAS nanoparticles serve as a temporary, low-cost mobilization agent that is administered intravenously and naturally cleared by the body. This disposable approach avoids the need for expensive, complex stem cell products while achieving the desired therapeutic effect through endogenous cell mobilization.
3Quantity of substance
If FAS is administered to mobilize stem cells, then stem cell concentration at injury site increases, but the mechanism of action must be precisely controlled
Solution Approach 1:
The FAS nanoparticles are engineered with specific physical and chemical parameters including fibrinogen coating density, albumin sphere size (typically 1-10 micrometers), and surface charge characteristics. These parameter optimizations enable natural binding to endothelial cells and activation of stem cell mobilization pathways without requiring complex external control systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of FAS effectively mobilizes stem cells and enhances their functionality, promoting renal repair and reducing the harmful effects of renal toxic agents and chemotherapy, as evidenced by improved renal function and histological recovery in animal models.
Implementation Method 1
certain protein nanoparticles or nanospheres can be administered via the intravenous route, which will result in the attachment of such nanoparticles to the cells residing in the endothelium of the blood vessels. In addition, the same nanospheres called 'Fibrinogen-coated albumin spheres (FAS)' can attach to bone marrow cells inside the bone marrow.
Implementation Method 2
administration of FAS intravenously has been shown to increase CD34+(stem) cells inside the bone marrow, followed by increased concentrations of certain 'more mature' cells in the peripheral blood
Data Source
AI summary
A product and method of using albumin nanoparticles for treating renal failure, dysfunction or damage in a subject by administering a therapeutically effective amount of an albumin nanoparticle suspension containing fibrinogen coated albumin spheres (FAS) to increase a concentration of stem cells or precursors cells in their original site and/or augment a function or effectiveness of them in vivo to mobilize these stem cells or the precursor cells toward a trauma site. The renal failure, dysfunction or damage can be caused by administration of a renal-harmful agent or a chemotherapy drug. The suspension can be administered prophylactically and prior to administration of the agent or drug. The method can include the testing for biological markers, such as osteopontin, in the urine of the subject, and using the concentration information of the biomarkers to predict dosage of the suspension that is effective in further treatment.